Sugi Predict

Sugi Predict / Compounds / SCHEMBL2447600

SCHEMBL2447600

SCHEMBL2447600

Cc1nccn1-c1ccc(Nc2nc3c(c(Cc4ccc(F)cc4)n2)CC(C(F)(F)F)CC3)cc1

nearest known ligand 0.37

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 1/20 0.37
▸ NR3C2 P08235 7/20 0.35
▸ SYK P43405 1/20 0.34
▸ TP53 P04637 1/20 0.33
▸ THRB P10828 1/20 0.33
▸ STAT6 P42226 1/20 0.32
▸ ALOX5 P09917 3/20 0.32
▸ ABL1 P00519 1/20 0.32
▸ BTK Q06187 1/20 0.32
▸ FABP4 P15090 1/20 0.32
▸ FABP5 Q01469 1/20 0.32
▸ JAK2 O60674 1/20 0.31
▸ KCNH3 Q9ULD8 2/20 0.31
▸ ALDH1A1 P00352 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2478009 0.88 NR3C2 (0.33) EGFRNR3C2SYKTP53THRB
SCHEMBL2485548 0.82 EGFR (0.38) EGFRNR3C2SYKTP53THRB
SCHEMBL2473812 0.81 EGFR (0.37) EGFRNR3C2SYKTP53THRB
SCHEMBL2478896 0.76 STAT6 (0.37) NR3C2SYKSTAT6JAK2ALDH1A1
SCHEMBL2446341 0.75 ROCK2 (0.40) EGFRSYKTP53JAK2ALDH1A1
SCHEMBL2482372 0.75 TUBB4A (0.37) EGFRSYKSTAT6JAK2ALDH1A1
SCHEMBL2480381 0.74 CYP3A4 (0.36) EGFRNR3C2SYKALDH1A1
SCHEMBL2480963 0.74 HTR2C (0.39) ALDH1A1
SCHEMBL2480019 0.74 ROCK2 (0.43) EGFRTP53STAT6ALDH1A1
SCHEMBL2481514 0.72 CYP3A4 (0.35) NR3C2SYKSTAT6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2367826-A1 MODULATORS OF AMYLOID BETA. AstraZeneca AB (SE) 2011-09-28 — — EP claimed
US-20100130495-A1 COMPOUNDS 563 ASTRAZENECA AB (SE) 2010-05-27 — — US claimed
WO-2010053438-A1 MODULATORS OF AMYLOID BETA. ASTRAZENECA AB (SE) 2010-05-14 — — WO claimed
US-8188101-B2 Dihydropyridopyrimidines for the treatment of AB-related pathologies ASTRAZENECA AB (SE) 2012-05-29 — — US disclosed
US-8188101-B2 Dihydropyridopyrimidines for the treatment of AB-related pathologies ASTRAZENECA AB (SE) 2012-05-29 — — US disclosed
US-8188101-B2 Dihydropyridopyrimidines for the treatment of AB-related pathologies ASTRAZENECA AB (SE) 2012-05-29 — — US disclosed
US-20100130495-A1 COMPOUNDS 563 ASTRAZENECA AB (SE) 2010-05-27 — — US disclosed
US-20100130495-A1 COMPOUNDS 563 ASTRAZENECA AB (SE) 2010-05-27 — — US disclosed
US-20100130495-A1 COMPOUNDS 563 ASTRAZENECA AB (SE) 2010-05-27 — — US disclosed
WO-2010053438-A1 MODULATORS OF AMYLOID BETA. ASTRAZENECA AB (SE) 2010-05-14 — — WO disclosed
WO-2010053438-A1 MODULATORS OF AMYLOID BETA. ASTRAZENECA AB (SE) 2010-05-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130495-A1 COMPOUNDS 563 BACE1, PSEN1, PSEN2 EGFR 2791/4885NR3C2 2599/4885SYK 641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.